vs
Apellis Pharmaceuticals, Inc.（APLS）与ZoomInfo Technologies Inc.（GTM）财务数据对比。点击上方公司名可切换其他公司
ZoomInfo Technologies Inc.的季度营收约是Apellis Pharmaceuticals, Inc.的1.6倍（$319.1M vs $199.9M），ZoomInfo Technologies Inc.净利率更高（10.9% vs -29.5%，领先40.4%），ZoomInfo Technologies Inc.同比增速更快（3.2% vs -5.9%），ZoomInfo Technologies Inc.自由现金流更多（$127.1M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 1.4%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
ZoomInfo Technologies Inc.是美国合规注册的数据服务商，通过数据采集、网页抓取等多元渠道汇总公开及非公开个人数据，同时收集企业、部门等商业主体信息，面向企业客户提供相关数据产品，助力客户开展精准营销等业务活动。
APLS vs GTM — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $319.1M |
| 净利润 | $-59.0M | $34.7M |
| 毛利率 | — | 84.0% |
| 营业利润率 | -25.6% | 17.0% |
| 净利率 | -29.5% | 10.9% |
| 营收同比 | -5.9% | 3.2% |
| 净利润同比 | -62.2% | 137.7% |
| 每股收益（稀释后） | $-0.40 | $0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $319.1M | ||
| Q3 25 | $458.6M | $318.0M | ||
| Q2 25 | $178.5M | $306.7M | ||
| Q1 25 | $166.8M | $305.7M | ||
| Q4 24 | $212.5M | $309.1M | ||
| Q3 24 | $196.8M | $303.6M | ||
| Q2 24 | $199.7M | $291.5M | ||
| Q1 24 | $172.3M | $310.1M |
| Q4 25 | $-59.0M | $34.7M | ||
| Q3 25 | $215.7M | $38.7M | ||
| Q2 25 | $-42.2M | $24.0M | ||
| Q1 25 | $-92.2M | $26.8M | ||
| Q4 24 | $-36.4M | $14.6M | ||
| Q3 24 | $-57.4M | $23.8M | ||
| Q2 24 | $-37.7M | $-24.4M | ||
| Q1 24 | $-66.4M | $15.1M |
| Q4 25 | — | 84.0% | ||
| Q3 25 | — | 83.7% | ||
| Q2 25 | — | 83.9% | ||
| Q1 25 | — | 84.5% | ||
| Q4 24 | — | 82.8% | ||
| Q3 24 | — | 84.4% | ||
| Q2 24 | — | 84.3% | ||
| Q1 24 | — | 86.0% |
| Q4 25 | -25.6% | 17.0% | ||
| Q3 25 | 48.7% | 21.2% | ||
| Q2 25 | -18.6% | 17.5% | ||
| Q1 25 | -50.0% | 16.5% | ||
| Q4 24 | -12.3% | 10.0% | ||
| Q3 24 | -24.0% | 14.3% | ||
| Q2 24 | -14.7% | -6.9% | ||
| Q1 24 | -36.0% | 13.9% |
| Q4 25 | -29.5% | 10.9% | ||
| Q3 25 | 47.0% | 12.2% | ||
| Q2 25 | -23.6% | 7.8% | ||
| Q1 25 | -55.3% | 8.8% | ||
| Q4 24 | -17.1% | 4.7% | ||
| Q3 24 | -29.2% | 7.8% | ||
| Q2 24 | -18.9% | -8.4% | ||
| Q1 24 | -38.5% | 4.9% |
| Q4 25 | $-0.40 | $0.11 | ||
| Q3 25 | $1.67 | $0.12 | ||
| Q2 25 | $-0.33 | $0.07 | ||
| Q1 25 | $-0.74 | $0.08 | ||
| Q4 24 | $-0.30 | $0.04 | ||
| Q3 24 | $-0.46 | $0.07 | ||
| Q2 24 | $-0.30 | $-0.07 | ||
| Q1 24 | $-0.54 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $179.9M |
| 总债务越低越好 | — | $1.3B |
| 股东权益账面价值 | $370.1M | $1.5B |
| 总资产 | $1.1B | $6.4B |
| 负债/权益比越低杠杆越低 | — | 0.88× |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $179.9M | ||
| Q3 25 | $479.2M | $135.0M | ||
| Q2 25 | $370.0M | $176.9M | ||
| Q1 25 | $358.4M | $140.5M | ||
| Q4 24 | $411.3M | $139.9M | ||
| Q3 24 | $396.9M | $147.7M | ||
| Q2 24 | $360.1M | $399.3M | ||
| Q1 24 | $325.9M | $440.2M |
| Q4 25 | — | $1.3B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $1.2B | ||
| Q1 24 | $93.1M | $1.2B |
| Q4 25 | $370.1M | $1.5B | ||
| Q3 25 | $401.2M | $1.5B | ||
| Q2 25 | $156.3M | $1.6B | ||
| Q1 25 | $164.2M | $1.6B | ||
| Q4 24 | $228.5M | $1.7B | ||
| Q3 24 | $237.1M | $1.7B | ||
| Q2 24 | $264.3M | $1.9B | ||
| Q1 24 | $266.7M | $2.0B |
| Q4 25 | $1.1B | $6.4B | ||
| Q3 25 | $1.1B | $6.4B | ||
| Q2 25 | $821.4M | $6.5B | ||
| Q1 25 | $807.3M | $6.4B | ||
| Q4 24 | $885.1M | $6.5B | ||
| Q3 24 | $901.9M | $6.4B | ||
| Q2 24 | $904.5M | $6.7B | ||
| Q1 24 | $831.9M | $6.8B |
| Q4 25 | — | 0.88× | ||
| Q3 25 | — | 0.87× | ||
| Q2 25 | — | 0.85× | ||
| Q1 25 | — | 0.75× | ||
| Q4 24 | — | 0.72× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.66× | ||
| Q1 24 | 0.35× | 0.61× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $143.5M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $127.1M |
| 自由现金流率自由现金流/营收 | -7.1% | 39.8% |
| 资本支出强度资本支出/营收 | 0.1% | 5.1% |
| 现金转化率经营现金流/净利润 | — | 4.14× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $389.3M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $143.5M | ||
| Q3 25 | $108.5M | $93.8M | ||
| Q2 25 | $4.4M | $108.9M | ||
| Q1 25 | $-53.4M | $119.2M | ||
| Q4 24 | $19.4M | $109.0M | ||
| Q3 24 | $34.1M | $18.2M | ||
| Q2 24 | $-8.3M | $126.3M | ||
| Q1 24 | $-133.0M | $115.9M |
| Q4 25 | $-14.3M | $127.1M | ||
| Q3 25 | $108.3M | $70.9M | ||
| Q2 25 | $4.4M | $86.9M | ||
| Q1 25 | $-53.4M | $104.4M | ||
| Q4 24 | $19.3M | $85.6M | ||
| Q3 24 | — | $600.0K | ||
| Q2 24 | $-8.4M | $115.2M | ||
| Q1 24 | $-133.3M | $103.1M |
| Q4 25 | -7.1% | 39.8% | ||
| Q3 25 | 23.6% | 22.3% | ||
| Q2 25 | 2.5% | 28.3% | ||
| Q1 25 | -32.0% | 34.2% | ||
| Q4 24 | 9.1% | 27.7% | ||
| Q3 24 | — | 0.2% | ||
| Q2 24 | -4.2% | 39.5% | ||
| Q1 24 | -77.3% | 33.2% |
| Q4 25 | 0.1% | 5.1% | ||
| Q3 25 | 0.0% | 7.2% | ||
| Q2 25 | 0.0% | 7.2% | ||
| Q1 25 | 0.0% | 4.8% | ||
| Q4 24 | 0.0% | 7.6% | ||
| Q3 24 | 0.0% | 5.8% | ||
| Q2 24 | 0.0% | 3.8% | ||
| Q1 24 | 0.2% | 4.1% |
| Q4 25 | — | 4.14× | ||
| Q3 25 | 0.50× | 2.42× | ||
| Q2 25 | — | 4.54× | ||
| Q1 25 | — | 4.45× | ||
| Q4 24 | — | 7.47× | ||
| Q3 24 | — | 0.76× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 7.68× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
GTM
暂无分部数据
